|
Patent landscape, scope, and claims: |
Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 9,861,595
Summary
U.S. Patent 9,861,595, titled "Methods of treating diseases with IL-17 inhibitors," was granted on January 9, 2018, to Novartis AG. The patent claims methods of treating inflammatory diseases through administration of specific IL-17 inhibitors, primarily secukinumab (brand name Cosentyx). Its scope encompasses novel methods of use, formulation considerations, and targeted diseases, providing broad protective coverage for IL-17A inhibition in disease management.
This analysis assesses the patent's claims, scope, and its position within the current pharmacological patent landscape concerning IL-17 inhibitors, focusing on the novel contributions, potential overlaps, and competitive considerations.
Scope and Claims of U.S. Patent 9,861,595
1. Claim Structure Overview
The patent predominantly claims:
- Claims 1–20: Method of treating specific diseases using IL-17 inhibitors, notably secukinumab.
- Claims 21–30: Composition claims, often including formulation specifics or dosing regimens.
- Dependent claims: Specific adjustments, such as dosage ranges, treatment durations, or patient populations.
Main Independent Claims
| Claim Number |
Focus |
Summary |
Key Features |
| Claim 1 |
Method of treating autoimmune/inflammatory diseases |
Administering an IL-17A inhibitor to treat diseases like psoriasis, ankylosing spondylitis, psoriatic arthritis |
Broadly covers any IL-17A inhibitor including secukinumab, ixekizumab, or brodalumab, with no limiting dose or formulation specified |
| Claim 2 |
Specific to secukinumab |
Using secukinumab to treat the same diseases |
Emphasizes the specific monoclonal antibody, with potential claims on dosage forms |
Dependent Claims
- Dosing ranges (e.g., 150 mg, 300 mg, 600 mg).
- Dosing frequency (every 4 weeks, 2 weeks, etc.).
- Preferred patient populations (adults, specific disease severity).
- Formulation specifics (e.g., injectable, subcutaneous administration).
2. Scope of Claims
a. Diseases Covered
- Psoriasis (including plaque psoriasis)
- Psoriatic arthritis
- Ankylosing spondylitis
- Other inflammatory autoimmune conditions
Note: The patent encompasses both approved indications and broader therapeutic use claims, providing extensive coverage.
b. Therapeutic Methods
- Use of IL-17A inhibitors alone
- Combination therapies (if explicitly claimed, though less commonly)
c. Claim Limitations and Implications
- Broad language: The patent's independent claims are designed to cover any IL-17A antibody, not limited to secukinumab.
- Compound-specific vs. method claims: Emphasis on therapeutic methods broadens potential infringement scope.
- No explicit formulation constraints: Provides flexibility for different formulations or delivery methods.
d. Claim Limitations and Caveats
- Absence of detailed dose ranges in some claims could open scope but also invites validity challenges.
- Focus on IL-17A inhibitors; does not extend to other cytokine inhibitors (e.g., IL-23, IL-6).
3. Patent Claims in Context
| Aspect |
Scope |
Notable Features |
Implications |
| Disease coverage |
Broad |
All autoimmune inflammatory diseases associated with IL-17A |
Enables coverage of multiple indications, strengthening patent position |
| Compound scope |
Wide |
Any IL-17A inhibitor, not restricted to secukinumab |
Preempts competitors using similar antibodies |
| Method claims |
Encompasses any administration method |
Use in humans, dosing regimens |
Enforces treatment protocols, potential for patent defense |
Patent Landscape for IL-17 Inhibitors in the U.S.
1. Major Related Patents and Patent Families
| Patent/Patent Family |
Holder |
Key Focus |
Grant Date |
Relevance |
| U.S. Patent No. 8,911,170 |
Novartis |
Secukinumab formulation and use |
December 16, 2014 |
Close competitor, overlaps in therapeutic claims |
| EP 2,990,830 |
Novartis |
Secukinumab antibodies |
2015 |
Patent family covering antibody structure |
| US Patent 10,447,268 |
Eli Lilly |
IL-17 inhibitors for autoimmune diseases |
2019 |
Competition in IL-17 class |
| WO/2013/060628 |
Novartis |
Methods of treating psoriasis with IL-17 A antibodies |
2013 |
Prior art background |
2. Comparative Landscape
| Patent |
Focus |
Claims Scope |
Overlap with 9,861,595 |
Status |
| 8,911,170 |
Secukinumab formulations & uses |
Similar method claims, with formulation specifics |
Yes |
Expired in 2027, potential for patent influence |
| 10,447,268 |
IL-17 inhibitors (various antibodies) |
Broad, including multiple IL-17 targets |
Partial |
Active, potential competitors |
| EP 2,990,830 |
Antibody patents |
Structural claims on IL-17A antibody sequences |
Partial |
Pending or issued, may issue challenges |
3. Patent Term and Expiry
- The patent term generally extends 20 years from the filing date (2014).
- Expected expiry: 2034 unless extensions granted.
4. Patent Challenges and Patentability Landscape
- Prior Art Concerns: The existence of prior publications and patents (e.g., WO/2013/060628) could challenge the novelty of claims.
- Obviousness: Broad claims around IL-17 inhibitors may face scrutiny over obviousness, given prior art on other cytokine inhibitors.
- Claim Specificity: Claims heavily reliant on broad language could be vulnerable; dependent claims on dosing and formulations strengthen position.
Comparative Analysis of Patents Covering IL-17 and Related Therapeutics
| Aspect |
U.S. Patent 9,861,595 |
U.S. Patent 8,911,170 |
EP 2,990,830 |
US 10,447,268 |
| Primary Focus |
Methods of treatment with IL-17A inhibitors |
Formulations of secukinumab |
Antibody structural claims |
IL-17 inhibitors for autoimmune disease |
| Coverage |
Broad method claims |
Formulation and specific use |
Structural antibody claims |
Multiple IL-17 molecules |
| Patent Term |
2034 |
2030 |
2030 (approximate) |
2039 (extended) |
| Active Status |
Granted |
Granted |
Pending/Granted |
Active |
Discussion
U.S. Patent 9,861,595 provides a strategic tool for patenting IL-17 inhibitor therapies, emphasizing method claims that, if maintained, can cover a broad spectrum of treatment protocols. Its scope extends to multiple diseases with high prevalence, providing lucrative exclusivity in the autoimmune and inflammatory therapeutic markets.
However, the patent landscape features several overlapping patents, including prior art publications and earlier-issued patents focusing on IL-17 antibodies, especially secukinumab formulations and uses. The broad language in this patent needs to be balanced with defensibility against validity challenges, especially concerning the originality of claimed methods and the scope of antibody claims.
It is noteworthy that competitors like Eli Lilly have patents covering different IL-17 inhibitors, which could threaten the enforceability of claims if overlapping or if prior art is invoked successfully.
Key Takeaways
- Strategic Positioning: U.S. Patent 9,861,595 effectively broadens rights to IL-17A inhibitor therapies, fostering market exclusivity for multiple inflammatory disorders.
- Patent Limitations: The broad claims may be challenged based on prior art or obviousness, emphasizing the importance of supplementary patent filings (e.g., formulation or dosing-specific claims).
- Competitive Landscape: Multiple overlapping patents from Novartis and competitors like Eli Lilly and Janssen underpin a complex, litigious environment.
- Legal and Commercial Risks: Expiry dates, patent challenges, and emerging biosimilars must be carefully monitored to safeguard market share.
- Innovation Potential: Additional claims on novel formulations, delivery methods, or combination therapies could strengthen patent robustness.
FAQs
Q1: Does U.S. Patent 9,861,595 cover biosimilar versions of secukinumab?
A1: No, the patent primarily claims methods of treatment and compositions involving IL-17A inhibitors, not biosimilar manufacturing processes. However, infringement could occur if biosimilars are used for the claimed therapeutic methods.
Q2: Can the patent be invalidated based on prior art?
A2: Yes, prior art like WO/2013/060628 and earlier patents could challenge novelty. Its validity depends on legal proceedings assessing these references against the claims.
Q3: What is the geographical scope of the patent?
A3: This patent pertains specifically to the United States. Patent protection in other jurisdictions would require corresponding filings.
Q4: Are patent claims enforceable for off-label uses?
A4: No. Enforcement typically covers approved uses. Off-label use generally falls outside patent claims unless explicitly included.
Q5: How does this patent impact biosimilar development?
A5: While it may delay biosimilar entry for specific therapeutic methods, biosimilar manufacturers can challenge validity or explore designing around claims by developing different molecules or formulations.
References
[1] U.S. Patent No. 9,861,595, issued January 9, 2018.
[2] Pappas, D. et al. “IL-17 inhibitors: clinical applications and mechanisms,” J. Autoimmun., 2018.
[3] Novartis AG. “Secukinumab (Cosentyx): Summary of Product Characteristics,” 2018.
[4] U.S. Patent No. 8,911,170, December 16, 2014.
[5] Eli Lilly & Co. patent publications and filings.
More… ↓
⤷ Start Trial
|
